GlassScriptPhysician profile
Mark H Meissner
NPI 1932285699
$43,254.78
in general payments reported to CMS, 2019-2025
13 companies · $6,944 in 2025
The $6,944 reported for 2025 was more than what 87% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,812 · 2020: $1,693 · 2021: $2,616 · 2022: $4,433 · 2023: $13K · 2024: $12K · 2025: $6,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,620 · Honoraria: $2,588 · Food and Beverage: $1,608 · Travel and Lodging: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,488.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,620.00 |
| Honoraria | $2,587.50 |
| Food and Beverage | $1,607.89 |
| Travel and Lodging | $397.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $18,172.12 | 2022-2025 | Venovo, Lutonix Drug Coated Balloon |
| Cook Incorporated | $17,480.00 | 2019-2024 | Zilver Vena |
| Abbott Laboratories | $3,215.00 | 2022-2025 | Tendyne, Xience Sierra |
| Medtronic, INC. | $1,249.15 | 2021-2025 | Venaseal, Heli-Fx Endoanchor System, Onyx 18 |
| Boston Scientific Corporation | $1,224.13 | 2022-2024 | Varithena Administration Pack |
| Medtronic Vascular, INC. | $828.77 | 2019-2020 | |
| Cook Medical LLC | $804.77 | 2019-2023 | Zilver Vena, Zilver Ptx |
| Philips North America LLC | $122.94 | 2022-2023 | |
| Tactile Systems Technology INC | $76.62 | 2019 | |
| Penumbra, INC. | $29.43 | 2024 | Ruby Coil |
| Organogenesis INC. | $27.01 | 2023 | Puraply |
| Surmodics, INC. | $24.84 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Meissner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.